Adularia
Adularia develops tumor‑targeted immunotherapies that harness microbiome‑derived immune pathways to boost the body’s natural anti‑cancer response. The company uses multi‑omics and AI‑driven small‑molecule design to identify and activate novel immune‑regulatory mechanisms. Its platform aims to improve efficacy and reduce side effects in oncology patients.
Traction –/10
HQ unknown
Updated 5 months ago
Funding
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Adularia develops tumor‑targeted immunotherapies that harness microbiome‑derived immune pathways to boost the body’s natural anti‑cancer response. The company uses multi‑omics and AI‑driven small‑molecule design to identify and activate novel immune‑regulatory mechanisms. Its platform aims to improve efficacy and reduce side effects in oncology patients.